The IPV vaccine is the Inactivated Polio Vaccine.
Understanding IPV
The Inactivated Polio Vaccine (IPV), also known as the Salk vaccine, was developed by Dr. Jonas Salk in 1955. It uses inactivated (killed) strains of all three poliovirus types to provide protection against polio. Unlike oral polio vaccines, IPV is administered through injection.
Key Features of IPV:
- Type: Inactivated vaccine.
- Developer: Dr. Jonas Salk.
- Year of Development: 1955.
- Virus Type: Uses killed strains of all three types of poliovirus.
- Administration: Given via injection.
How IPV Works:
IPV works by introducing killed poliovirus strains into the body. This prompts the immune system to produce antibodies against the virus without causing infection. These antibodies then protect against future exposure to live poliovirus.
Benefits of IPV:
- Provides immunity against polio.
- Prevents paralysis caused by the poliovirus.
- Safe for most individuals.
| Vaccine Name | Acronym | Type | Developer | Year | Virus Type | Administration |
|---|---|---|---|---|---|---|
| Inactivated Polio Vaccine | IPV | Inactivated | Dr. Jonas Salk | 1955 | All three types of poliovirus | Injection |
